loureirin b has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, M; Li, R; Wu, G; Yang, Z; Zhang, C | 1 |
| Bai, X; Fan, L; He, T; Hu, D; Liu, J; Shi, J; Su, L; Tang, C; Tao, K; Wang, Y | 1 |
2 other study(ies) available for loureirin b and Disease Models, Animal
| Article | Year |
|---|---|
Loureirin B alleviates cardiac fibrosis by suppressing Pin1/TGF-β1 signaling.
Topics: Animals; Cardiomyopathy, Restrictive; Cardiotonic Agents; Cell Proliferation; Collagen; Disease Models, Animal; Echocardiography; Fibrosis; Immunochemistry; Mice; Myocardium; NIMA-Interacting Peptidylprolyl Isomerase; Resins, Plant; Signal Transduction; Transforming Growth Factor beta1 | 2022 |
Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway.
Topics: Adolescent; Adult; Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cicatrix, Hypertrophic; Disease Models, Animal; Down-Regulation; Extracellular Matrix; Female; Fibroblasts; Humans; Male; Matrix Metalloproteinases; Myofibroblasts; Rabbits; Resins, Plant; RNA, Messenger; Smad Proteins; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1; Young Adult | 2015 |